JHVEPhoto
- The US FDA approved Teva Pharmaceutical Industries’ (TEVA) Degvema (denosumab-adet), a biosimilar to Amgen’s (AMGN) Xgeva (denosumab), which is indicated to prevent bone damage and complications in cancer patients.
- Approval was based on analytical and clinical data showing Degvema has
